February 05, 2010
Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).
January 26, 2010
FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).
October 19, 2009
Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.
September 18, 2009
The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.
September 15, 2009
Advanced Life Sciences Holdings announced that the FDA has granted Orphan Drug Designation to Restanza (cethromycin), its once daily oral antibiotic, for the prophylactic treatment of plague and tularemia.